However, the exogenous addition of FGF9 in HCC cells activated ERK and JNK, and led to a decrease in sorafenib sensitivity, which suggests the FGF-dependent HSC-HCC cross-talk in liver cancers [42]. Here, FGF9 is linked to hepatocellular carcinoma.